Exponential Biotherapies, Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, May 2011, Pages: 27

Exponential Biotherapies, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Exponential Biotherapies, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Exponential Biotherapies, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Exponential Biotherapies, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Exponential Biotherapies, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Exponential Biotherapies, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Exponential Biotherapies, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Exponential Biotherapies, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Exponential Biotherapies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Exponential Biotherapies, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Exponential Biotherapies, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Exponential Biotherapies, Inc. Snapshot
Exponential Biotherapies, Inc. Overview
Key Information
Key Facts
Exponential Biotherapies, Inc. – Research and Development Overview
Key Therapeutic Areas
Exponential Biotherapies, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Exponential Biotherapies, Inc. – Pipeline Products Glance
Exponential Biotherapies, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Exponential Biotherapies, Inc.–Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Exponential Biotherapies, Inc. – Drug Profiles
EA-230
Product Description
Mechanism of Action
R&D Progress
Drug for Radiation Sickness
Product Description
Mechanism of Action
R&D Progress
EA-230
Product Description
Mechanism of Action
R&D Progress
Drug for Anthrax
Product Description
Mechanism of Action
R&D Progress
Drug for Avian Flu
Product Description
Mechanism of Action
R&D Progress
Exponential Biotherapies, Inc. – Pipeline Analysis
Exponential Biotherapies, Inc. – Pipeline Products by Therapeutic Class
Exponential Biotherapies, Inc. – Pipeline Products by Route of Administration
Exponential Biotherapies, Inc. – Pipeline Products by Molecule Type
Exponential Biotherapies, Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Exponential Biotherapies, Inc., Deals Summary, 2004 to 2011
Exponential Biotherapies, Inc. Detailed Deal Summary
Venture Financing
Exponential Biotherapies Secures $5 Million In Venture Financing
Exponential Biotherapies Secures $10.5 Million In Venture Financing
Exponential Biotherapies Secures $9 Million In Venture Financing.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Exponential Biotherapies, Inc. – Pipeline by Therapy Area and Indication, 2011
Exponential Biotherapies, Inc. – Pipeline by Stage of Development, 2011
Exponential Biotherapies, Inc. – Monotherapy Products in Pipeline, 2011
Exponential Biotherapies, Inc. - Phase II, 2011
Exponential Biotherapies, Inc. - Phase I, 2011
Exponential Biotherapies, Inc. - Pipeline By Therapeutic Class, 2011
Exponential Biotherapies, Inc. – Pipeline By Route of Administration, 2011
Exponential Biotherapies, Inc. – Pipeline By Molecule Type, 2011
Exponential Biotherapies, Inc., Deals Summary, 2004 to 2011

List of Figures
Exponential Biotherapies, Inc. – Pipeline by Therapy Area and Indication, 2011
Exponential Biotherapies, Inc. – Pipeline by Stage of Development, 2011
Exponential Biotherapies, Inc. – Monotherapy Products in Pipeline, 2011
Exponential Biotherapies, Inc. – Pipeline By Therapeutic Class, 2011
Exponential Biotherapies, Inc. – Pipeline By Route of Administration, 2011
Exponential Biotherapies, Inc. – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Amazon - Point of Realization in 2013?
• Accenture - Profile - US